MedTrace Logo

Early Postoperative Day 0 Chest Tube Removal After Thoracoscopic Minor Surgeries

NCT04670523 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2026-04-29

No results posted yet for this study

Summary

The safe conditions for early chest tube removal have been progressively questioned and redefined around reliable digital air flow criteria and extension of liquid threshold accepted. Nevertheless, in current practice, the chest tube remains in restricting early mobilization and optimal compliance with ERAS programme, during the first crucial 24 h after surgery. Thus, to go further, the investigators decide to assess in this study the safety of POD 0 chest tube removal after minor thoracic operations in patients in health condition tolerating operation and anesthesia.

Conditions

  • Lung Pathologies of Unclear Etiology

Interventions

PROCEDURE

Early postoperative day 0 (POD 0) chest tube removal.

Chest tube removal is a standard bedside intervention after lung resections. Its time point is normally defined according a traditional standard airleak threshold. Traditionally, in our department this threshold will be respected not earlier than 1 day after the operation. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow \<20 mL/ min on digital suction device) but already in the operating room after wound closure (POD 0). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).

PROCEDURE

Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).

Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Patrick Dorn, PD · Chief, Department of General Thoracic Surgery, Inselspital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-06
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04670523 on ClinicalTrials.gov